Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 27 Apr 2023
In the second week of life, 83 percent of newborns who were fed formula milk had Clostridium difficile and Clostridium perfringens, but by the end of the third week, all infants had these infections.
Read Full NewsIZAR-1: Sonelokimab Meets Phase 3 End Points for PsA
Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.
Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.
What The FDA Psychedelic Hearing Means for Psychiatrists
A new phase 4 trial, OCTAGON, will test a rapid, predefined corticosteroid-tapering schedule in patients with generalized myasthenia gravis treated with ravulizumab.
A phase 4 study is evaluating whether adults with chronic inflammatory demyelinating polyneuropathy can transition from intravenous immunoglobulin to subcutaneous efgartigimod PH20 without first experiencing disease worsening.
Real-world 12‑month results from WeSMA, a phase 4 study, showed that oral risdiplam is well tolerated in adults with SMA, with stable motor function and consistent safety findings.
1.
Decoding calcifications in breast cancer: Towards personalized medicine
2.
Immunotherapy Combo Active in Advanced PD-L1-Negative HNSCC
3.
Progress in Early Cancer Diagnosis; Breast Cancer in Younger Women; Diet and Cancer.
4.
Nanoparticle vaccine prevents multiple cancers and stops metastasis in mice
5.
Researchers study effects of cannabis on sedation, cancer treatment symptoms
1.
Beyond the Biopsy: Decoding Tumor Biology Through the Lens of Radiogenomics
2.
CAR T + Ibrutinib in R/R Mantle Cell Lymphoma: Phase 2 TARMAC Study Insights
3.
Oncologic Emergencies: Diagnosis and Treatment
4.
A Closer Look at White Blood Cells in Urine: Uncovering the Causes and Treatments
5.
Cardiotoxicity Beyond Anthracyclines: Redefining Risk in the Cardio-Oncology Era
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
3.
Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.
4.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
5.
Understanding Common Causes of Abnormal Blood Counts
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge